H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on ImmunoGen to $21 from $15 and keeps a Buy rating on the shares. Interim data from the Phase 2 CADENZA study highlights pivekimab’s manageable safety profile with no capillary leak syndrome, the analyst tells investors in a research note. The firm believes pivekimab demonstrated a manageable safety and tolerability profile in this large dataset, which compares favorably to tagraxofusp that carries a black-boxed warning of life-threatening capillary leak syndrome.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMGN:
- ImmunoGen Rises on Promising Phase 3 Elahere Data in Ovarian Cancer
- ImmunoGen announces $200M common stock offering
- ImmunoGen upgraded to Overweight at Piper after ‘overwhelmingly positive’ data
- H.C. Wainwright reiterates Buy on ImmunoGen following MIRASOL ‘homerun’
- ImmunoGen upgraded to Overweight from Neutral at Piper Sandler